Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
• 5 min read
• Published on 13 August 2025
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Executive Conviction In The GLP-1 Market
There are few signals in the market quite as loud as a chief executive opening his own wallet. When the people who run the show start buying their own company’s shares, especially after a spot of bad news, I tend to sit up and pay attention. It’s one thing to issue a confident press release, it’s quite another to put your own money where your mouth is. This is precisely what we saw recently at Eli Lilly, and to me, it speaks volumes about the real opportunity in the weight-loss drug market.
View the full Basket:Executive Conviction In The GLP-1 Market
Let’s be clear, the stock market can be a terribly emotional beast. A clinical trial stumbles, a headline flashes red, and suddenly everyone is running for the exits. When Eli Lilly’s share price took a knock after some disappointing trial data, the herd reacted predictably. But the shepherds, in this case the company’s own executives, didn’t panic. Instead, they went shopping, picking up millions of pounds worth of their own stock.
Now, why would they do that? It’s simple. They have a front row seat. They understand the nuances of their drug pipeline, the manufacturing schedules, and the long term strategy in a way that no analyst or armchair pundit ever could. Their buying suggests they see the market’s wobble as a temporary squall, not a fundamental change in the weather. They believe the shares are cheap, and they are backing that belief with cold, hard cash. For any investor, that’s a powerful vote of confidence.
View the full Basket:Executive Conviction In The GLP-1 Market
The fuss is all about a class of drugs known as GLP-1s. Originally for diabetes, they’ve turned out to be astonishingly effective for weight loss. This isn’t some herbal tea fad, it’s a genuine medical breakthrough that is changing lives and, in the process, creating one of the biggest new markets in modern healthcare history. Novo Nordisk kicked things off with its blockbusters Ozempic and Wegovy, proving a colossal demand existed. Eli Lilly followed with its own heavy hitters, Mounjaro and Zepbound, turning this into a heavyweight title fight.
The sheer scale of the potential market is staggering. We are talking about hundreds of millions of people globally. Right now, only a tiny fraction of them are using these treatments. This isn't a mature market, it's a market in its infancy. The current supply shortages are, ironically, a good sign. It shows that demand is completely outstripping the ability of these giants to produce the drugs, a problem any business would love to have.
View the full Basket:Executive Conviction In The GLP-1 Market
Of course, this journey will not be a straight line upwards. Investing in pharmaceuticals is always a bit of a rollercoaster. Clinical trials can and do disappoint. Competition is heating up, with smaller players like Altimmune trying to develop the next big thing. Patents will eventually expire. These are all valid risks to consider.
However, the executive action at Eli Lilly provides a crucial piece of the puzzle. It suggests that the long term growth story remains firmly on track, despite any short term noise. The investment case here is not about a single trial result, it is about a fundamental shift in how we treat one of the world’s biggest health crises. To me, this is a classic case of following the smart money, a strategy encapsulated by the Executive Conviction In The GLP-1 Market theme. It focuses on the very signal that caught my eye in the first place, the confidence of those who know best. For the patient investor, the current volatility might just be the opportunity you’ve been waiting for.
View the full Basket:Executive Conviction In The GLP-1 Market
View the full Basket:Executive Conviction In The GLP-1 Market
View the full Basket:Executive Conviction In The GLP-1 Market
View the full Basket:Executive Conviction In The GLP-1 Market
View the full Basket:Executive Conviction In The GLP-1 Market
View the full Basket:Executive Conviction In The GLP-1 Market
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article